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Résumé en
anglais
In this work, multifunctional lipid nanocapsules (M-LNC) were designed to combine
the activity of the cytotoxic drug paclitaxel (PTX) with the immunostimulant CpG.
This nanosystem, consisting of modified lipid nanocapsules coated with a cationic
polymeric shell composed of chitosan (CS), was able to allocate the hydrophobic
drug PTX in the inner oily core, and to associate onto the surface the genetic
material CpG. The CS-coated LNC (CS-LNC), showed a narrow size distribution with
an average size of 70nm and a positive zeta potential (+25mV). They encapsulated
PTX in a high amount (98%), and, due to the cationic surface charge, were able to
adsorb CpG without losing stability. As a preliminary in vitro study, the apoptotic
effect on GL261 glioma cells was investigated. The drug-loaded CS-LNC exhibited
the ability to interact with glioma cells and induce an important apoptotic effect in
comparison with blank systems. Finally, the M-LNC made of CS-LNC loaded with
both CpG and PTX were tested in vivo, injected via convention enhanced delivery
(CED) in GL261-glioma-bearing mice. The results showed that the overall survival of
mice treated with the M-LNC was significantly increased in comparison with the
control, Taxol(®), or the separated injection of PTX-loaded LNC and CpG. This effect
was also confirmed by magnetic resonance imaging (MRI) which revealed the
reduction of tumor growth in the animals treated with CpG and PTX-loaded M-LNC.
All these findings suggested that the developed M-LNC could potentiate both CpG
immunopotency and PTX antitumor activity by enhancing its delivery into the tumor
microenvironment.
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